Special Report: Dimerix has received the initial payment of ¥300 million (A$3.2 million) in line with its recently announced ...

Index fell 7.66% in February to be the second-worst performing sector for the month as the local bourse felt the pressure of ...

Dimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries ...

Some healthcare analysts believe Neuren Pharmaceuticals (ASX:NEU) shares should be worth more than double their current soft ...

Dimerix Limited ( ($AU:DXB) ) has provided an update. Dimerix Limited has announced the quotation of 147,275 ordinary fully paid securities on the ...

Investor reaction to PolyNovo's (ASX:PNV) half-year numbers shows how even seemingly minor earnings misses can result in a ...

In a report released on February 21, Tanushree Jain from Petra Capital maintained a Buy rating on Dimerix Limited (DXB – Research Report), with ...

Taiba also has a right to negotiate a licence to develop and commercialise DMX-200 in any additional indications in the licensed territories that Dimerix may achieve for DMX-200. The minimum term for ...

Dr Nina Webster is the CEO and managing director of Dimerix (ASX:DXB), which in mid-CY25 is due to report the second interim results of its ACTION3 global phase III trial of lead drug DMX-200 to treat ...

Dimerix pursues new product concepts and applies scientific knowledge to the discovery of products from early stage development through to commercialisation.